On New Year’s day GoLocalProv announced that it had selected Stephen Salloway, M.D. as its Man of the Year for 2019. Dr. Salloway, a world leader in Alzheimer’s research, is director of Neurology and the Memory and Aging Program at Butler Hospital and Martin M. Zucker professor of psychiatry and human behavior, professor of neurology at Alpert Medical School of Brown University. The honor comes after Dr. Salloway was also inducted into the Rhode Island Heritage Hall of Fame in May, 2019.
Dr. Salloway’s professional accomplishments and contributions to the field of Alzheimer’s research are staggering and continue to grow. As the founding director of the Memory and Aging Program at Butler Hospital, for the last 22 years he has, from his offices on the Butler Hospital campus right here in Rhode Island, played a major role in advancing the study and treatment of Alzheimer’s disease and dementia for the entire world.
Under his direction the program has conducted over 100 clinical trials and research studies. Each of them has provided another small step forward in the fight against Alzheimer’s through deeper insights and understanding into how the disease develops, how it can be diagnosed earlier and more accurately, and how it might then be treated more effectively or even prevented altogether. Today, those many small steps are building to what Dr. Salloway and his team hope will be a giant leap in Alzheimer’s treatment in the next several years.
The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
Sam Slezak originally set out to become a trainer for professional athletes. Here’s how and why he became a project manager for a landmark national Alzheimer’s study instead.
The study seeks to identify new cognitive and neural biomarkers of preclinical Alzheimer’s disease, which would aid in earlier diagnosis and interventional treatment for the disease.
Caregiver to both her young husband and her father with dementia, now she’s supporting others in the caregiver journey.
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
MAP Director Dr. Stephen Salloway, along with other international leaders in the fight against Alzheimer’s, talk with the Providence Journal and WJAR NBC10 about how the fight to end Alzheimer’s continues despite coronavirus.
Aducanumab, an investigational drug for the treatment for Alzheimer’s disease, has been submitted to the FDA for approval with a request for Priority Review. If approved, it would become the first therapy to reduce the clinical decline of Alzheimer’s disease.
RI Chosen as 1 of 5 Sites for First Nationwide Study of Lifestyle Intervention to Reduce Risk of Cognitive Decline
The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is sponsored by the Alzheimer’s Association and is the first such study to be conducted in a large, diverse group of Americans across the United States.
Louisa Thompson, Ph.D., research scientist at Brown University and Butler Hospital, will evaluate how app-based and online cognitive tests might be used to detect subtle changes in memory and thinking associated with Alzheimer’s.